 TRACON Pharmaceuticals NASDAQ:TCON Inc announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial proceed as planned. The update follows a review of three-week safety data from more than 20 patients enrolled into the trial by the end of June 2022. 